Denali Therapeutics

Phase A — Understand the business

Lens 1 · Company Overview

Denali Therapeutics is a South San Francisco biopharma (incorporated Delaware 2015; Nasdaq: DNLI) that "discovers and develops therapeutics to defeat neurodegenerative diseases and lysosomal storage diseases". Founded by three ex-Genentech scientists — Ryan Watts (CEO, former head of Genentech Neuroscience), Marc Tessier-Lavigne (former Genentech CSO, later Stanford president), and Alexander Schuth. Commenced operations May 2015; no product was approved for commercial sale and the company had generated no product revenue as of the FY2025 10-K.

What changed everything: On March 25, 2026, the FDA granted accelerated approval to AVLAYAH™ (tividenofusp alfa-eknm, formerly DNL310) for the neurologic manifestations of Hunter syndrome (MPS II) in pediatric patients ≥5 kg, before advanced neurologic impairment. AVLAYAH is the first FDA-approved biologic engineered to cross the blood-brain barrier and reach both the CNS and periphery — the validating event for Denali's entire reason to exist. So as of this dossier, Denali is an early-commercial company (one approved drug, launch underway) sitting on a still-clinical pipeline.

The business model in plain terms: A platform company. The crown jewel is the Transport Vehicle (TV) technology — a protein engineered to bind the transferrin receptor (TfR1), which is enriched on brain endothelium, at a fine-tuned affinity ("bind, then let go") so it shuttles a therapeutic cargo across the BBB by receptor-mediated transcytosis. The TV is a chassis that carries four cargo classes:

• ETV (Enzyme TV) — lysosomal enzymes for storage diseases (AVLAYAH = ETV:IDS; DNL126 = ETV:SGSH; DNL952 = ETV:GAA).
• PTV (Protein TV) — e.g. DNL593 = PTV:PGRN (progranulin) for FTD-GRN.
• ATV (Antibody TV) — e.g. the discontinued TAK-920/DNL919 (ATV:TREM2).
• OTV (Oligonucleotide TV) — antisense oligos delivered IV instead of intrathecally; early-stage (alpha-synuclein/Parkinson's, Tau/DNL628).

Customers / payers: Ultimately payers and rare-disease treatment centers. AVLAYAH's addressable US population is ~500 living MPS II patients with ~30 new diagnoses/year. This is ultra-orphan — revenue comes from very few patients at very high price (see Lens 7 pricing).

Contract / payment structure: Denali monetized future AVLAYAH economics aggressively pre-launch: (1) a synthetic royalty sold to Royalty Pharma — $275M for a 9.25% royalty on tividenofusp net sales, contingent on FDA accelerated approval ($200M received in Q1 2026); (2) sale of the Rare Pediatric Disease Priority Review Voucher for ~$195M gross, granted on approval. Together ~$470M of non-dilutive capital crystallized off a single approval — the financing story is as important as the science here.

Lens 2 · Supply Chain (CDMO / manufacturing)

Denali is a fully outsourced (CDMO-reliant) manufacturer — it owns the IP and the molecule, not the plants. Named/structural stakeholders along the chain:

• Upstream (drug substance/product): "We have established a third-party supply chain for tividenofusp alfa and, if approved … plan to continue to rely on third-party contract manufacturers for its commercial supply". Specific CDMO names are not disclosed in the filings on disk (n/a — not named in filings); this is a single-/limited-source dependency typical of a complex fusion-protein biologic and is a real chokepoint for a weekly-infused product.
• The molecule: a recombinant IDS enzyme fused to a TfR1-binding Fc — manufacturing complexity is materially higher than a small molecule; cold-chain biologic.
• Delivery / channel: weekly IV infusion at 15 mg/kg, administered at infusion centers; Denali built "a right-sized team in commercial and medical affairs to support tividenofusp alfa and additional ETV product launches". For some ex-US or capacity reasons it has "begun to enter into arrangements with third parties for the commercialization of DNL310".
• Partners as channel/funding nodes: Biogen (LRRK2/BIIB122 — Biogen runs and funds the Parkinson's trials), historically Takeda and Sanofi (both partnerships now wound down on the relevant assets — see Lens 9). Royalty Pharma sits in the chain as a financial counterparty owning 9.25% of AVLAYAH's top line.

Chokepoint read: Single approved product + outsourced biologic manufacturing of a weekly infusion = supply continuity and scale-up are genuine launch risks. Not a differentiator; a dependency.

Lens 3 · Competitive Advantages (moats)

This is where Denali earns its valuation — or doesn't.

• Platform / process moat (the real one): The TV/TfR1 transcytosis platform is now clinically and regulatorily validated — AVLAYAH is the first BBB-crossing biologic the FDA has ever approved. That is a moat made of (a) a decade of process know-how on TfR1 affinity tuning, (b) a deep IP estate around the TV constructs, and (c) regulatory precedent — Denali has now walked the FDA through accepting a CSF heparan-sulfate surrogate for accelerated approval, a path competitors must still blaze. Durable for the duration of the patents + the data advantage.
• Orphan/regulatory exclusivity: Orphan drug designation (DNL310 granted Feb 2019) plus biologic exclusivity; ultra-rare indications deter competitors on pure market-size grounds.
• Bargaining power — over payers: High for an ultra-orphan with no CNS-penetrant alternative — AVLAYAH is the only approved therapy addressing the neurologic (cognitive/behavioral) burden of Hunter syndrome, the community's stated greatest unmet need. Existing ERT (Takeda's Elaprase) treats the body but cannot cross the BBB.
• Bargaining power — over suppliers (CDMOs): Low-to-moderate — Denali needs its contract manufacturers more than they need it at current scale.
• Where the moat is thin: It protects the platform, not any single indication's commercial outcome. And the platform's value is a function of how many more programs convert — which the LUMA failure (Lens 5/12) just called into question for the non-enzyme cargoes.

Lens 4 · Segments

Denali has no commercial product segmentation — through FY2025 it was pre-revenue, so there is no `` segment table to anchor (segments.csv empty by construction). Historically, the only "revenue" was collaboration revenue from partners (Biogen/Takeda/Sanofi), which has now largely ended:

• FY2023: $330.5M collaboration revenue (net loss only $145.2M).
• FY2024 & FY2025: $0 collaboration revenue.

The "segments" that matter going forward are programs, broken out in Lens 5. Geographically, the launch is US-first (AVLAYAH approved US only; global submissions pending COMPASS).

---

Phase B — Measure performance (+clinical variant: pipeline-by-phase, catalyst calendar, rNPV/runway)

Lens 5 · Pipeline by Phase (replaces "Earnings Result")

The asset table is the company. Status as of Jun 2026:

Discontinued / dead: DNL343 (eIF2B, ALS) — failed HEALEY Phase 2/3 (no effect on progression or NfL), wound down 2025. TAK-920/DNL919 (ATV:TREM2, Alzheimer's) — discontinued by Takeda 2023–25, "narrow therapeutic window". Sanofi DNL788/SAR443820 (ALS/MS) — HIMALAYA/K2 discontinued 2024; Sanofi license terminated Feb 24 2025 (no further milestones/royalties to Denali).

Pleiotropic/financial profile of the lead: AVLAYAH efficacy basis — CSF heparan sulfate reduced 91% at Week 24, maintained to Week 153 (92%); manageable early hemoglobin decreases, no discontinuations. This is the data that won accelerated approval.

P&L reality (for context, not the thesis): Q1-2026 — R&D $103.8M, G&A $33.5M, total opex $137.4M, net loss $128.4M, EPS −$0.69. FY2025 — R&D $418.8M, G&A $136.6M, net loss $512.5M, EPS −$2.97. The loss is widening (FY24 −$422.8M → FY25 −$512.5M) as commercial/launch spend layers onto R&D.

Lens 6 · Management Focus & Sentiment (calls/communications)

No transcripts on disk (transcripts/ empty), so this is ``. Management's narrative has pivoted hard from "platform promise" to "commercial execution + platform de-risking." CEO Ryan Watts called the launch his "greatest professional moment". The stated 2026 priorities: (1) AVLAYAH US launch — 2026 framed as "activation and access," with "adoption acceleration" expected in 2027; (2) DNL126 toward accelerated approval; (3) DNL593 FTD-GRN data by end-2026.

Tone shift: Pre-2026 calls were dominated by pipeline-by-phase and partnership economics. The recurring 2026 phrase is "right-sized" commercial build — management signaling capital discipline on the launch. What they stopped saying: the Parkinson's/LRRK2 program as a near-term value driver — after LUMA (May 21) the LRRK2 story is reframed to the BEACON carrier readout (H1 2027) only. Honest disclosure of bad news (LUMA, DNL343, DNL952 hold) has been prompt — a positive governance signal.

Lens 7 · Catalyst Calendar + Mechanism Comps (replaces "Comps" P/E table)

Catalyst calendar (what de-risks or kills, and when):

Mechanism comps (by modality, not P/E — but multiples for the early-commercial rare-disease cohort for valuation context):

• Direct MPS II competitor: REGENXBIO RGX-121 (AAV gene therapy) — received an FDA CRL in Feb 2026 (eligibility criteria, natural-history control, surrogate-endpoint concerns). This clears Denali's most direct near-term rival and leaves AVLAYAH as the only approved CNS-penetrant MPS II therapy.
• Peripheral ERT incumbent: Takeda Elaprase (idursulfase) — body-only, cannot cross BBB; the COMPASS comparator.
• Valuation peers (early-commercial rare/orphan): Ultragenyx (RARE) ~6.5x TTM sales, BioMarin (BMRN) ~5.5x, Ionis (IONS) ~9–10x P/S. Caveat: these are revenue multiples; DNLI has negligible trailing revenue, so an EV/Sales comp is not yet meaningful — DNLI forward EV/peak-sales is the honest frame (see Lens 11). A clean EV/Sales for DNLI today = n/a — not yet revenue-generating at scale.

Lens 8 · Stock-Price Catalysts (5-yr pattern)

What actually moves DNLI:

• Binary clinical/regulatory readouts dominate. The stock trades as a basket of catalyst lottery tickets. AVLAYAH approval (Mar 2026) was the up-leg; LUMA failure (May 2026) the down-leg.
• Already-priced failures barely move it: when DNL343 (ALS) failed Jan/Mar 2025, "shares remained largely unmoved … investors had already factored in the demise," though the stock was then ~half its 52-week high — the market had written off the small-molecule legacy programs.
• Financing events: the $275M Royalty Pharma deal + ~$200M equity raise (late 2025) and the $195M PRV sale are recurring liquidity catalysts — Denali repeatedly converts milestones into non-dilutive cash.
• Read: the market reacts to de-risking of the platform's breadth, not to any single orphan's economics. AVLAYAH's ~$525M peak (Lens 11) is too small to explain a $3.3B cap on its own — the cap is platform optionality, which is exactly what LUMA just discounted.

---

Phase C — Judge people & books (+clinical: + science & exclusivity)

Lens 9 · Management

• Track record: Ryan Watts (CEO/co-founder) built and led Genentech's Neuroscience Labs, pioneering BBB-delivery methods, over an 11-year tenure. He has now done the thing the field said was nearly impossible — gotten a BBB-crossing biologic approved. That is a career-defining, credibility-cementing delivery. Co-founder Marc Tessier-Lavigne is a globally prominent neuroscientist (ex-Genentech CSO; note the well-publicized 2023 controversy over his academic papers that led to his Stanford resignation — a reputational asterisk on a co-founder, though not implicating Denali's data).
• Tenure & skin in the game: Founder-led since 2015. Insider ownership not quantified here (insider-transactions.csv absent — n/a, not sourced); founder/CEO continuity is a positive archetype for a platform company.
• Capital allocation: Disciplined and creative. They (a) monetized future royalties and the PRV for ~$470M non-dilutive rather than pure equity dilution; (b) "right-sized" the commercial build; (c) killed failing programs promptly (DNL343, DNL952 hold, accepted partner exits) rather than throwing good money after bad. This is the right behavior for a high-failure-rate modality.
• Red flags: Heavy reliance on partnerships that keep ending (Takeda, Sanofi both exited their lead Denali assets) — either bad luck on the assets or a pattern of partners losing conviction; worth watching. No related-party/comp red flags surfaced.
• Founder vs. professional: Founder-scientist archetype — appropriate for a science-platform company at the validate-then-commercialize inflection.

Lens 10 · Forensic Red Flags + Regulatory

Accounting (`` unless noted):

• Revenue recognition: Minimal risk today — no product revenue recognized through FY2025; collaboration revenue is gone. The forward watch-item is how AVLAYAH net revenue and the Royalty Pharma 9.25% carve-out are presented once launch revenue flows.
• The new $199.6M "liability related to the revenue participation right": Denali received $200M cash from Royalty Pharma and booked it as a liability (not revenue) — appropriate (it's a financing, repaid via future royalties), plus a $36M intangible appeared. Non-cash interest accretion on this liability will be a recurring below-the-line drag — model it, don't be surprised by it. This is conservative accounting, not aggressive.
• Cash vs. earnings: Net loss is real cash burn (no SBC-driven gimmickry inflating non-GAAP; SBC ~$25M/quarter is disclosed plainly). No receivables/inventory red flags (pre-commercial).
• Going concern: None — $1.05B cash, runway "at least the next twelve months" (through ≥Q2 2027).
• Pre-funded warrants: 28.3M pre-funded warrants ($0.01 exercise) outstanding — true share count is effectively higher than the ~158.7M issued; weighted diluted shares already ~186.6M in Q1-2026 EPS. Don't undercount dilution.

Regulatory findings (required):

• SEC: No Litigation Releases and no AAERs naming Denali, 2021-06-20 → 2026-06-20.
• Non-SEC (FDA/DOJ/FTC, web): No enforcement actions, consent decrees, fines, or penalties surfaced. The FDA relationship is favorable (just granted accelerated approval). The only regulatory "risk" is structural: accelerated approval is conditional on the COMPASS confirmatory trial — failure could lead to withdrawal.
• 10-K Item 3 (Legal Proceedings): No material litigation disclosed of note in the filings on disk.
• Conclusion: No material regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Item 3 as of 2026-06-20.

Science & exclusivity (+clinical add): Mechanism validated in humans and at the FDA (TfR1 transcytosis → CSF HS reduction → approval). IP estate around TV constructs is the durable asset; orphan exclusivity + biologic exclusivity protect AVLAYAH. KOL/scientific-founder credibility high (Watts/Tessier-Lavigne pedigree). Patent-cliff/LOE timing not enumerated in filings on disk (n/a); for a 2026-approved biologic, exclusivity runway is long.

---

Phase D — Project & stress-test

Lens 11 · rNPV + Runway-to-Catalyst (replaces EPS projection)

This is a sum-of-the-parts / runway question, not an EPS line.

Runway: $1.05B cash + marketable securities (Mar 31 2026); burn $128M/quarter ($500M/yr, partly offset by ~$470M of crystallized non-dilutive cash and incoming AVLAYAH revenue). Runway comfortably reaches the DNL593 end-2026 readout and the BEACON H1-2027 readout — the two value-inflection catalysts ahead. Runway is not the binding constraint here; thesis-conviction is.

rNPV of the lead (AVLAYAH), rough:

• Peak US sales ~$525M. `` cross-check: ~500 US patients × ~$500K avg annual net (weight-blended, post-discount from the ~$270K–$811K WAC range ) × ~70% treated-share ≈ ~$175M near-term → ~$525M peak with adult/label expansion + ex-US. The BofA peak and my bottom-up are in the same zip code.
• AVLAYAH rNPV : at ~$525M peak, ~80% gross margin, less the **9.25% Royalty Pharma carve-out**, a high (~90%+) PoS now that it's *approved* (the residual risk is COMPASS confirmatory + commercial ramp, not regulatory), discounted ~10% → **~$1.5–2.5B** of value attributable to the AVLAYAH + near-line ETV franchise (DNL126 adds a second orphan of similar shape). Every input ; range is wide by construction.
• Implication: The approved/near-approved enzyme franchise plausibly underwrites most of the ~$3.3B market cap. That means the platform optionality (FTD-GRN, OTV/Tau, LRRK2-carriers, future cargoes) is being valued at roughly $0.8–1.8B net of cash — and that bucket is exactly what LUMA just made the market discount. The stock is not obviously cheap and not obviously expensive; it is "fairly priced for the enzyme business + cheap optionality if the platform breadth re-rates."

No forecast.ts create logged — --watchlist unattended mode (the binary I'd track is "DNL593 FTD-GRN Phase 1/2 shows a clear progranulin/biomarker effect by 2026-12-31," est. p≈0.55; logged centrally if promoted).

Lens 12 · Bull vs Bear

Bull case. Denali just proved the un-proven: a biologic that crosses the BBB, validated by an FDA approval — the platform is real, not a slide. AVLAYAH is the only approved therapy for the neurologic burden of Hunter syndrome, its most direct rival (RGX-121) just took a CRL, and ultra-orphan pricing ($270K–$811K/yr) means even ~500 patients is a high-margin annuity. Management converted the win into ~$470M non-dilutive cash and a clean balance sheet with multi-year runway. If DNL126 (MPS IIIA) and DNL593 (FTD-GRN, data end-2026) read out positive, Denali becomes a serial rare-CNS franchise on a repeatable chassis — and the optionality the market is giving away (OTV/Tau, LRRK2 carriers, future cargoes, partner economics) re-rates the whole platform. This is the rare biotech where the technology moat is durable beyond any single drug.

Bear case. Three things can permanently impair the story: (1) The platform's breadth is the valuation, and it's cracking — LUMA's Phase 2b Parkinson's failure (>90% target engagement and it still didn't work) says target engagement ≠ efficacy, and the LRRK2/sporadic-PD multi-billion TAM just evaporated; if FTD-GRN also disappoints end-2026, DNLI re-rates to "an enzyme company" worth a fraction of $3.3B. (2) AVLAYAH is small and conditional — ~$525M peak doesn't carry a $3.3B cap alone, and accelerated approval can be withdrawn if the COMPASS confirmatory (vs Elaprase) fails years out. (3) Cash burn is widening (FY25 −$512M) and ~10% of float is short — the skeptics are positioned. Pre-mortem (18 months out, thesis broke): FTD-GRN data underwhelmed end-2026, AVLAYAH launch uptake was slow (ultra-rare diagnosis/access friction), and the "platform" narrative collapsed to one approved orphan — the stock halved. Contrarian view the market is refusing to see: the enzyme franchise (where the TV works most reliably — you're replacing a missing protein, not modulating a complex disease) may be worth more, and the neuro-disease-modification franchise (Parkinson's/Alzheimer's/ALS, where Denali keeps failing) worth less, than the blended multiple implies. The bull and bear are really arguing about which half of the platform is real.

Lens 13 · Devil's Advocate (short-seller)

I'm short DNLI. Here's the dismantling:

• The growth case died in May. Bulls bought Denali for "BBB platform → giant neuro markets." LUMA is the tell: in early-stage Parkinson's, with >90% peripheral LRRK2 inhibition and CSF target engagement, BIIB122 did nothing on the primary or secondaries. If you can hit the target that hard and not move the disease, the entire "drug the CNS and big neurodegeneration falls" thesis is suspect. Alzheimer's (DNL919) already died; ALS (DNL343, DNL788) already died. The pattern is the platform delivers cargo but the cargoes don't cure brain disease — except where the biology is trivial (replace a missing enzyme).
• You're paying a platform multiple for a single ultra-orphan drug. Strip the ~$1B cash and AVLAYAH's ~$525M-peak rNPV barely supports half the EV; the rest is optionality the market just learned to distrust. That's asymmetric down into the FTD-GRN readout.
• The approved drug is itself conditional. Accelerated approval rests on a CSF-HS surrogate; the COMPASS confirmatory vs Elaprase must show real clinical benefit or the FDA can pull it — and the agency has been tightening on surrogate-based rare-disease approvals (it CRL'd RGX-121 partly on whether HS predicts benefit). Same surrogate doubt hangs over AVLAYAH long-term.
• Partners keep walking. Takeda and Sanofi both exited their lead Denali assets. Sophisticated pharma counterparties with full data access chose to leave. Why are public-market bulls more confident than Denali's own partners were?
• What single scenario permanently impairs it: FTD-GRN (DNL593) misses end-2026 → "enzymes only" → de-rate to RARE/BMRN-style ~5–6x of a ~$525M peak, i.e. well below today. Plausibility: moderate-to-high. The 10% short interest says I'm not alone.

Lens 14 · Management Questions (ordered by information value)

1. After LUMA's failure despite >90% LRRK2 target engagement, what is your updated probability that the TV platform can modulate complex neurodegeneration (vs. enzyme/protein replacement), and how does that change pipeline prioritization?
2. What specifically must the COMPASS confirmatory trial show, by when, to convert AVLAYAH's accelerated approval to full — and what is your contingency if it reads ambiguous?
3. Walk us through AVLAYAH's first two quarters of launch: patients on therapy, infusion-center activations, and payer coverage decisions — what's the actual uptake curve vs. your internal plan?
4. For DNL593 (FTD-GRN) end-2026: what biomarker/clinical bar would you call a clear win, and what would you consider a fail?
5. Given Takeda and Sanofi both exited their lead Denali assets, what did they see — and why should the market weight their exit less than your conviction?
6. What is the realistic ceiling on AVLAYAH net revenue including ex-US and adult/label expansion, net of the 9.25% Royalty Pharma carve-out?
7. How do you think about the FDA's tightening posture on CSF heparan-sulfate as a surrogate (it featured in the RGX-121 CRL) for your current and future accelerated-approval filings?
8. What's the manufacturing scale-up and second-source plan for a weekly-infused biologic, and where is supply single-sourced today?
9. With FY25 burn at ~$512M, what is the path to cash-flow breakeven, and at what revenue level — or is another monetization/raise contemplated?
10. What is your capital-allocation priority for the ~$470M of non-dilutive proceeds — pipeline, commercial build, or balance-sheet cushion?
11. For DNL126 (MPS IIIA), is the FDA-aligned accelerated path materially de-risked by AVLAYAH's precedent, or do you expect program-specific scrutiny?
12. What is the strategic future of the OTV (oligonucleotide) cargo class after the IV-delivery data — is that the next platform leg or a science project?
13. How should investors value the BEACON (LRRK2-carrier) H1-2027 readout given LUMA — is the carrier hypothesis genuinely independent of the sporadic-PD failure?
14. What would it take — data or strategic — for you to consider partnering or selling the company versus going it alone as a commercial entity?
15. Five years out, is Denali a focused rare-enzyme commercial company or a broad neuro-platform — and what evidence in the next 18 months tells us which?

---